<DOC>
	<DOCNO>NCT02737072</DOCNO>
	<brief_summary>The main purpose study evaluate safety tolerability chemokine ( C-X-C Motif ) receptor 4 ( CXCR4 ) peptide antagonist LY2510924 durvalumab phase 1a 1b participant advanced refractory solid tumor .</brief_summary>
	<brief_title>A Study LY2510924 Durvalumab Participants With Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Phase 1a : Have histologic cytologic confirmation advance solid tumor Have least 1 measurable lesion assessable use standard technique Response Evaluation Criteria Solid Tumours ( RECIST ) v1.1 Have adequate organ function Have performance status 0 1 Eastern Cooperative Oncology Group ( ECOG ) scale Have provide tissue newly obtain core excisional biopsy tumor lesion recent biopsy define ≤3 year since last documented progression disease Have estimate life expectancy ≥12 week , judgment investigator Have serious concomitant systemic disorder include human immunodeficiency virus ( HIV ) , active hepatitis B virus ( HBV ) , active HCV , active autoimmune disorder disease require high dose steroid Have bowel obstruction , history presence inflammatory enteropathy extensive intestinal resection chronic diarrhea Have evidence interstitial lung disease symptomatic may interfere detection management suspect drugrelated pulmonary toxicity active , noninfectious pneumonitis Have active infection require systemic therapy Have prior therapy antiprogrammed cell death 1 ( PD1 ) , antiPDL1 , antiPDL2 , anticytotoxic T lymphocyteassociated antigen4 antibody Moderate severe cardiovascular disease Have symptomatic uncontrolled brain metastasis , spinal cord compression , leptomeningeal disease require concurrent treatment Have receive live vaccine within 30 day first dose study treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>immuno-oncology</keyword>
</DOC>